IZMENJENO PONAŠANJE U TESTU OTVORENOG POLJA KOD ŽIVOTINJA SA EKSPERIMENTALNIM PROSTATITISOM

Aleksa Zubelić; Božo Knežević; Željko Grubač; Nikola Šutulović; Olivera Stanojlović; Dragan Hrnčić

doi:10.5937/mp70-22242

Aleksa Zubelić Laboratorija za neurofiziologiju, Institut za medicinsku fiziologiju ‘‘Rihard Burjan‘‘, Medicinski fakultet, Univerzitet u Beogradu
Božo Knežević Laboratorija za neurofiziologiju, Institut za medicinsku fiziologiju ‘‘Rihard Burjan‘‘, Medicinski fakultet, Univerzitet u Beogradu
Željko Grubač Laboratorija za neurofiziologiju, Institut za medicinsku fiziologiju ‘‘Rihard Burjan‘‘, Medicinski fakultet, Univerzitet u Beogradu
Nikola Šutulović
Olivera Stanojlović
Dragan Hrnčić

DOI: https://doi.org/10.5937/mp70-22242

Sažetak

Uvod: Hronični prostatitis/sindrom hroničnog pelvičnog bola (eng. Chronic prostatitis/Chronic Pelvic Pain Syndrome, CP/CPPS) jedan je od najučestalijih kliničkih sindroma genitourinarnog trakta kod reproduktivno sposobnih muškaraca. Smatra se da je CP/CPPS često udružen sa psihosocijalnim poremećajima koji uključuju i anksioznost. Uprkos velikom broju kliničkih studija, mehanizmi ove povezanosti nisu u potpunosti razjašnjeni, te bi eksperimentalni modeli pomogli u rasvetljavanju ovih veza.
Cilj: Cilj ovog rada je da se testom otvorenog polja ispitaju lokomotorna aktivnost i ponašanje povezani sa anksioznošću kod pacova sa eksperimentalno izazvanim CP/CPPS.
Materijal i metode: Mužjaci pacova soja Wistar albino su nasumično raspodeljeni u kontrolnu i eksperimentalnu grupu. U eksperimentalnoj grupi indukovan je razvoj CP/CPPS intraprostatičnom injekcijom 3% λ-karagenena, dok je kontrolna grupa bila tretirana na isti način 0,9% natrijum-hloridom (NaCl). Razvoj CP/CPPS je praćen merenjem praga bola na mehanički stimulus upotrebom elektronskog von Frejevog (eVF) esteziometra. Životinje su pojedinačno testirane u otvorenom polju 7 dana nakon intraprostatične injekcije.
Rezultati: Eksperimentalne životinje su u testu otvorenog polja pokazale statistički značajno skraćenje pređenog puta i vremena ambulatornog kretanja, smanjenje broja propinjanja na zadnje ekstremitete, skraćenje vremena provedenog u centru otvorenog polja, kao i povećanje indeksa tigmotaksije u odnosu na kontrolne životinje.
Zaključak: Rezultati ovog rada ukazuju na anksiogene efekte CP/CPPS u eksperimentalnoj grupi.

Ključne reči: hronični prostatitis, sindrom hroničnog pelvičnog bola, test otvorenog polja, anksioznost, pacovi

Reference

Passavanti, M.B, Pota V, Sansone P, Aurilio C, De Nardis L, Pace M.C. Chronic Pelvic Pain: Assessment, Evaluation, and Objectivation. Pain Res. Treat. 2017; 2017:1-15.

Daniels NA, Link CL, Barry MJ, McKinlay JB. Association between past urinary tract infections and current symptoms suggestive of chronic prostatitis/chronic pelvic pain syndrome. J Natl Med Assoc. 2007; 99:509–516.

Arora, H.C, Shoskes D.A. Gut microbiome and chronic prostatitis/chronic pelvic pain syndrome. Ann. Transl. Med. 2017; 5:30.

Brünahl C, Dybowski C, Albrecht R, Riegel B, Höink J, Fisch M, Löwe B. Mental disorders in patients with chronic pelvic pain syndrome (CPPS). J. Psychosom. Res. 2017; 98:19–26.

Fu W, Zho Z, Liu S, Li Q, Yao J, Li W, Yan J. The Effect of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) on Semen Parameters in Human Males: A Systematic Review and Meta-Analysis. PLoS ONE. 2014; 9:94-91.

Hrncic, D., Sutulovic, N, Grubac, Z, Rasic-Markovic A, Stanojlovic O. The central nervous system is not imunoprivileged: Inflammation and epileptogenesis. Vojnosanit. Pregl. 2018; 75(8):820–825.

M. Potts, J. Male Pelvic Pain: Beyond Urology and Chronic Prostatitis. Curr. Rheumatol. 2016; 12:27–39.

Dersh J, Polatin PB, Gatchel RJ. Chronic pain and psychopathology:research findings and theoretical considerations. Psychosom Med. 2002; 64:773–786.

Marques L, Robinaugh DJ, LeBlanc NJ, Hinton D. Cross-cultural variations in the prevalence and presentation of anxiety disorders. Expert Rev Neurother. 2011; 11:313–322.

Spielberger C.D, Gorsuch RL, Lushene RE. Manual for the state-trait anxiety inventory (STAI). Palo Alto, CA: Consulting Psychologists Press Inc. 1983.

Pontari MA, McNaughton-Collins M, O’leary MP, Calhoun EA, Jang T. A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int. 2005; 96:559–565.

Clemens JQ, Meenan RT, O’Keeffe Rosetti MC, Kimes T, Calhoun EA. Prevalence of and risk factors for prostatitis: population based assessment using physician assigned diagnoses. J Urol. 2007; 178:1333–1337.

Collins MM, Meigs JB, Barry MJ, Walker Corkery E, Giovannucci E. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol. 2002; 167:1363–1366.

Berghuis JP, Heiman JR, Rothman I, Berger RE. Psychological and physical factors involved in chronic idiopathic prostatitis. J Psychosom Res. 1996; 41:313–325.

J.J.M.C.H de la Rosette JJ, Hubregtse MR, Karthaus HF, Debruyne FM. Results of a questionnaire among Dutch urologists and general practitioners concerning diagnostics and treatment of patients with prostatitis syndromes. Eur Urol. 1992; 22:14–18.

Chung SD, Lin HC. Association between chronic prostatitis/chronic pelvic pain syndrome and anxiety disorder: a population-based study. PLoS One. 2013; 15:8-9.

Kraeuter AK, Guest PC, Sarnyai Z. The Open Field Test for Measuring Locomotor Activity and Anxiety-Like Behavior. Methods Mol Biol. 2019; 1916:99-103.

Radhakrishnan, R., Nallu, R.S. Development and characterisation of a novel animal model of prostate inflammation-induced chronic pelvic pain. Inflammopharmacology. 2009; 17:23–28.

Zeng, F, Chen H, Yang J, Wang L, Cui Y, et al. Development and Validation of an Animal Model of Prostate Inflammation-Induced Chronic Pelvic Pain: Evaluating from Inflammation of the Prostate to Pain Behavioral. J Neurosci. 2017; 38:1583–1590.

Zhang K, Zeng, X, Chen, Y, Zhao R., Wang H., Wu J. Therapeutic effects of Qian-Yu decoction and its three extracts on carrageenan-induced chronic prostatitis/chronic pelvic pain syndrome in rats. BMC Comp. Altern. Med. 2017; 17:75.

Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003; 463:3-33.

Simon P, Dupuis R, Costentin J. Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behavioural Brain Research. 1994; 61:59-64.

Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol. 2003; 70:83-244.

Öztekin, İ., Akdere, H., Can, N., Aktoz, T., Arda, E., Turan, F.N., 2015. Therapeutic Effects of Oligonol, Acupuncture, and Quantum Light Therapy in Chronic Nonbacterial Prostatitis. Evid Based Complement Alternat Med. 2015; 2015:1–8.

Steimer T. Animal models of anxiety disorders in rats and mice: some conceptual issues. Dialogues Clin Neurosci. 2011; 13:495-506.

Ramos A, Correia EC, Izidio GS, Bruske GR. Genetic selection of two new rat lines displaying different levels of anxiety-related behaviors. Behav Genet 2003; 33:657-668.

Luheshi GN, Bluthe RM, Rushforth D, et al.Vagotomy attenuates the behavioural but not the pyrogenic effects of interleukin-1 in rats. Auton Neurosci. 2000; 85:127–32.

Breser, M.L, Salazar, F.C, Rivero, V.E, Motrich, R.D. Immunological Mechanisms Underlying Chronic Pelvic Pain and Prostate Inflammation in Chronic Pelvic Pain Syndrome. Front. Immunol. 2017; 8:898.

Jakobsson J, Bjerke M, Sahebi S, Isgren A, Ekman CJ, Sellgren C, et al. Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. JPN. 2015; 40:250–258.

Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA psychiatry. 2015; 72:268–275.

Wohleb ES, Patterson JM, Sharma V, Quan N, Godbout JP, Sheridan JF. Knockdown of interleukin-1 receptor type-1 on endothelial cells attenuated stress-induced neuroinflammation and prevented anxiety-like behavior. J Neurosci. 2014; 34:2583–2591.

Bergink V, Megen HJ, Westenberg HG. Glutamate and anxiety. Eur Neuropsychopharmacol. 2004; 14:175-183.

Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med. 2006; 73:941-949.

Vaquero-Lorenzo C et al. Positive association between SAT-1-1415T/C polymorphism and anxiety. Am J Med Genet B Neuropsychiatr Genet. 2008; 150B(4):515-519.

Zou JY, Crews FT. TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res. 2005; 1034:11–24.

Vezzani A, Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology. 2015; 96:70–82.

Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010; 67:446–457.

Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009; 71:171–186.

Durackova Z. Some current insights into oxidative stress. Physiol Res. 2010; 59:459-69.

Bouayed J, Rammal H, Soulimani R. Oxidative stress and anxiety: relationship and cellular pathways. Oxid Med Cell Longev. 2009; 2:63-67.

Rammal H, Bouayed J, Younos C, Soulimani R. Evidence that oxidative stress is linked to anxietyrelated behaviour in mice. Brain Behav Immun. 2008; 22:1156-1159.

Hovatta I, Juhila J, Donner J. Oxidative stress in anxiety and comorbid disorders. Neurosci Res. 2010; 68:261-275.

Salim S, Sarraj N, Tanej M, Saha K, Tejada MV. Moderate treadmill exercise prevents oxidative stressinduced anxietylike behavior in rats. Behav Brain Res. 2010; 208:545-552.

Vazquez B, Devinsky O. Epilepsy and anxiety. Epilepsy Behav. 2003; 4:20-25.